Marion Merrell Dow's Cardizem Injectable approved
Calcium channel blocker will be launched before the end of November. Cardizem Injectable (diltiazem hydrochloride) is approved for atrial fibrillation or atrial flutter and paroxysmal supraventricular tachycardia. The contraindications and warnings are generally similar to those associated with Cardizem tablets; there are additional contraindications for Cardizem Injectable in patients with an accessory bypass tract, in patients who recently received intravenous beta blockers, and for patients with ventricular tachycardia. The product is approved in 25 mg/5 ml and 50 mg/10 ml doses....
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth